Preclinical evaluation of Mito-LND, a targeting mitochondrial metabolism inhibitor, for glioblastoma treatment
Tongxuan Guo(Xuzhou Medical College), Xuejiao Liu(Xuzhou Medical College)
Cited by 12
Related Papers
CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
|Journal of Hematology & Oncology|2016|80
MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways
|Frontiers in Oncology|2021|46
RETRACTED ARTICLE: GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death
|Cell Death and Disease|2021|42
MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR‐induced NF‐κB activation
|Journal of Cellular and Molecular Medicine|2020|32
Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma
|Cell Communication and Signaling|2023|24